AU2002217043A1 - Salmonella vaccine - Google Patents

Salmonella vaccine

Info

Publication number
AU2002217043A1
AU2002217043A1 AU2002217043A AU1704302A AU2002217043A1 AU 2002217043 A1 AU2002217043 A1 AU 2002217043A1 AU 2002217043 A AU2002217043 A AU 2002217043A AU 1704302 A AU1704302 A AU 1704302A AU 2002217043 A1 AU2002217043 A1 AU 2002217043A1
Authority
AU
Australia
Prior art keywords
vaccines
bacteria
relates
salmonella vaccine
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217043A
Inventor
Petrus Johannes Maria Nuijten
Maarten Hendrik Witvliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU2002217043A1 publication Critical patent/AU2002217043A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to live attenuated Salmonella strains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates to vaccines based upon these bacteria, to the use of such bacteria in the manufacture of vaccines and to methods for the preparation of such vaccines.
AU2002217043A 2000-11-16 2001-11-15 Salmonella vaccine Abandoned AU2002217043A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00204022 2000-11-16
EP00204022 2000-11-16
EP00204387 2000-12-08
EP00204387 2000-12-08
PCT/EP2001/013396 WO2002040046A1 (en) 2000-11-16 2001-11-15 Salmonella vaccine

Publications (1)

Publication Number Publication Date
AU2002217043A1 true AU2002217043A1 (en) 2002-05-27

Family

ID=26072856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217043A Abandoned AU2002217043A1 (en) 2000-11-16 2001-11-15 Salmonella vaccine

Country Status (10)

Country Link
US (1) US7045122B2 (en)
EP (1) EP1345621B1 (en)
JP (1) JP2004513646A (en)
AT (1) ATE413888T1 (en)
AU (1) AU2002217043A1 (en)
CA (1) CA2429120C (en)
DE (1) DE60136563D1 (en)
ES (1) ES2316492T3 (en)
HU (1) HUP0302612A3 (en)
WO (1) WO2002040046A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2005092372A2 (en) * 2004-02-06 2005-10-06 Cerus Corporation Modified bacillus anthracis vaccine compositions and methods of use thereof
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080311135A1 (en) * 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
KR101123390B1 (en) * 2009-03-30 2012-03-23 서울대학교산학협력단 Live-attenuated Salmonella vaccine and method for production of it
WO2011019134A2 (en) * 2009-08-11 2011-02-17 전북대학교산학협력단 Vaccine composition including salmonella microorganism variants for preventing fowl typhoid
BRPI1000173A2 (en) * 2010-01-04 2011-08-23 Fundacao De Amparo A Pesquisa modified bacterial strain and use thereof
CN102586489B (en) * 2010-04-09 2013-09-18 山东农业大学 Detection of infection of avian anemia viruses in pathologic material by combination of polymerase chain reaction (PCR) and nucleic acid probe and dot blot hybridization technology
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
KR101856736B1 (en) * 2016-02-29 2018-05-11 (주)비손바이오로직스 Endotoxin-reduced Salmonella trivalent inactivated vaccine composition for preventing fowl typhoid and Salmonellosis
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109486714B (en) * 2018-12-07 2020-08-04 扬州大学 Salmonella typhimurium attenuated isolate and application thereof
CN110218668B (en) * 2019-05-21 2020-04-03 扬州大学 Inert carrier salmonella and potential application thereof
CN110257276B (en) * 2019-05-21 2020-03-24 扬州大学 Inert carrier escherichia coli and potential application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
ES2133311T3 (en) * 1990-11-21 1999-09-16 Univ Washington RECOMBINANT AVIRULENT SALMONELLA ANTIFERTILITY VACCINES.
JPH07206705A (en) * 1993-11-03 1995-08-08 American Cyanamid Co Live in ovo vaccine
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB2434636B (en) 2004-11-10 2009-03-18 Martin Professional As Method and apparatus for project light with gel

Also Published As

Publication number Publication date
HUP0302612A3 (en) 2004-10-28
DE60136563D1 (en) 2008-12-24
CA2429120A1 (en) 2002-05-23
US7045122B2 (en) 2006-05-16
JP2004513646A (en) 2004-05-13
ES2316492T3 (en) 2009-04-16
HUP0302612A2 (en) 2003-11-28
EP1345621B1 (en) 2008-11-12
EP1345621A1 (en) 2003-09-24
ATE413888T1 (en) 2008-11-15
WO2002040046A1 (en) 2002-05-23
US20040052802A1 (en) 2004-03-18
CA2429120C (en) 2012-03-13

Similar Documents

Publication Publication Date Title
AU2002217043A1 (en) Salmonella vaccine
IL154913A0 (en) Composition comprising immunogenic microparticles
MY125202A (en) Vaccine
EP1032417A4 (en) Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens
MXPA05013973A (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL136131A0 (en) Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
WO2001034801A3 (en) Recombinant gelatin in vaccines
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
AU1234697A (en) Streptococcus equi vaccine
FR21C1005I1 (en)
WO2002075507A3 (en) Anti-bacterial vaccine compositions
GB9806449D0 (en) Attenuated bacteria useful in vaccines
MX9702524A (en) Attenuated viruses and method of making the same.
WO2003031599A3 (en) Live attenuated salmonella strains for producing vaccines
AU2001258373A1 (en) Method for identifying helicobacter antigens
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
BR0111785A (en) Compositions and methods for treating candidiasis
EP1074266A3 (en) Live attenuated bacteria for use in a vaccine
AU2001234616A1 (en) Vaccine composition, process and methods
AU1386100A (en) Stable, attenuated rabies virus mutants and live vaccines thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
MY127452A (en) Vaccines.
WO2004089408A3 (en) Vaccine preparations comprising live or killed attenuated mutant neisseria bacteria
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor